$MIST

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2614433d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage

Raymond James issued an earnings preview for seven commercial-stage biopharma firms ahead of Q2 2026 results. It highlighted Insmed (INSM) launch growth, United Therapeutics (UTHR) Tyvaso revenue of about $480M-$490M, Jazz (JAZZ) potential beat, Ionis (IONS) Tryngolza value, PTC (PTCT) $150M-$160M Q2 sales, Tonix (TNXP) access expansion, and Milestone (MIST) Cardamyst trajectory.

Milestone Pharmaceuticals (Nasdaq: MIST) said it granted 288,000 stock options under its 2021 Inducement Plan to hire six new employees. Options were granted July 1, 2026 with an exercise price of $1.32 per share (the closing price that day). Vesting is over four years: 25% after one year, then monthly installments for 36 months, subject to continued service.

Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2617859d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Milestone Pharmaceuticals Inc. 2019 Equity Incentive Plan, As Amended MILESTONE PHARMACEUTICALS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 10, 2019 APPROVED BY THE SHAREHOLDERS: APRIL 29, 201

Milestone Pharmaceuticals Inc. has filed its definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders, to be held virtually on June 10, 2026. Shareholders will vote on the election of eight directors, the ratification of PricewaterhouseCoopers LLP as auditor, an increase of 6,800,000 shares under the 2019 Equity Incentive Plan, and a non-binding advisory vote on executive compensation. The Board recommends voting FOR all proposals, emphasizing strong governance practices and the need for additional shares to attract and retain talent, especially following the FDA approval of CARDAMYST™.

Milestone Pharmaceuticals (NASDAQ:MIST) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, contributing to a consensus "Moderate Buy" rating among analysts with an average target price of $8.00. The stock is currently trading around $2.15, and institutional ownership is notably high at 86.18%, indicating significant hedge fund interest. The company recently surpassed quarterly EPS estimates, though negative EPS is still projected for the full fiscal year.

PDUFA Target Date of December 13, 2025 for CARDAMYST™ ( etripamil ) Nasal Spray in Paroxysmal Supraventricular Tachycardia ...

Data show consistent efficacy, safety, and tolerability findings across multiple clinical trials that evaluated self-administered etripamil Data show consistent efficacy, safety, and tolerability findings across multiple clinical trials that evaluated ...

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index dipping more than 250 points on Friday. The Dow traded down 0.60% to 44,382.58 while the NASDAQ rose 0.06% to 20,643.06. The S&P 500 also fell, dropping, 0.23% to 6,266.23. In trading on Friday, health care ...